Jazz Pharma Xyrem favorably viewed by narcolepsy patients, says Cantor After attending an FDA meeting on narcolepsy, Cantor Fitzgerald believes that patients have a high awareness of Xyrem and are favorably predisposed to the medication. The firm reiterates a Buy rating on Jazz.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals price target raised to $130 from $110 at UBS UBS raised its price target on Jazz Pharmaceuticals to adjust its discount rate to reflect a change in risk premium. The firm notes the company's business continues to perform above expectations and expects additional business activities to diversify the company. Shares are Buy rated.